spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  eFFECTOR 

 HSMN NewsFeed - 8 May 2026
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 8 Nov 2021
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Nov 2021
SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting
Devices
 HSMN NewsFeed - 23 Jul 2021
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
Biopharmaceuticals Radiology Licensing
 HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Feb 2021
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 Oct 2020
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
Biopharmaceuticals
 HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Aug 2020
Qualigen Therapeutics Appoints Amy Broidrick to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Aug 2020
Phosplatin Therapeutics Completes $18.4 Million Private Financing Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Jun 2020
Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 8 Jun 2020
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2020
Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Oct 2019
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Sep 2019
Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Aug 2019
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2019
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX(R) Platform Technology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Jul 2019
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2019
IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win(R) Immunotherapy in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2019
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2019
Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Nov 2018
RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2018
Olympus 3D/FlexDex(R) for Minimal Access Surgery Simplifies Suturing, Redefines Robotics
Devices Surgery Product Launch
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Aug 2018
Olympus and FlexDex Announce Exclusive Distribution Agreement
Devices Surgery Distribution
 HSMN NewsFeed - 27 Jun 2018
Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Mar 2018
Bionik Laboratories Corp. and Curexo Enter Exclusive Distribution Agreement for Sale of Robotic Rehabilitation Systems in U.S. and South Korea
Devices Distribution
 HSMN NewsFeed - 16 Jan 2018
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2017
Morphotek(R), Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab(R)
Biopharmaceuticals Diagnostics Oncology Licensing
 HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 16 Mar 2017
Oncolytics Biotech(R) Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN(R) in Combination with Imnovid(R) or Revlimid(R) in Patients with Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Feb 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Aug 2016
Ambrx Closes $45M Round of Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Jul 2016
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 1 Jun 2016
Oncternal Therapeutics Merges with Tokalas to Form Clinical-Stage Biotechnology Company with Promising Oncology Pipeline
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing
 HSMN NewsFeed - 19 Feb 2016
eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 19 Jan 2016
Allakos Successfully Completes Dosing in Phase 1 Clinical Trial of AK001 and Announces Expansion of its Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2015
eFFECTOR Therapeutics Raises $40 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Dec 2015
European Commission Approves Amgen's IMLYGIC(TM) (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Dec 2015
eFFECTOR Therapeutics Appoints Alana McNulty Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 Sep 2014
Titan Medical Inc. Appoints Dr. Dennis Fowler as Executive Vice President, Clinical and Regulatory Affairs
Devices Personnel
 HSMN NewsFeed - 24 Jun 2014
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2014
Abingworth Raises £225m ($375m) in its Tenth Life Sciences Fund
Biopharmaceuticals Devices Venture Capital
 HSMN NewsFeed - 20 May 2013
eFFECTOR Therapeutics Raises $45 Million in Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 14 Jun 2012
GenMark Diagnostics Appoints Stephen T. Worland, Ph.D. to Board of Directors
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 7 Jun 2012
Titan Medical Inc. Announces Addition of Dr. Dennis L. Fowler, MD, MPH as Development Consultant
Devices Personnel
 HSMN NewsFeed - 15 Feb 2012
Titan Medical Inc. Enters Into Exclusive License Agreement with Columbia University for Novel Single Port Robotic Surgery System
Devices Surgery Licensing
 HSMN NewsFeed - 9 Feb 2011
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
Biopharmaceuticals Dermatology Acquisitions
 HSMN NewsFeed - 5 Oct 2010
NormOxys, Inc. Appoints Dr. Gerard Riedel as Vice President, Regulatory Affairs and Program Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2010
NormOxys Secures $17.5 Million Series B Financing to Advance Lead Drug Candidate into Clinical Studies for Two Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Dec 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jun 2009
Paulo F. Costa Joins MacroGenics Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Mar 2009
Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 25 Mar 2008
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
GlaxoSmithKline and Tolerx Form Worldwide Collaboration for Development and Commercialization of Novel Medication
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Sep 2007
Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Sep 2007
Antibody Engineering Company f-star Raises EUR 6.0 Million in Series A Financing From Aescap Venture and Atlas Venture
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Jul 2007
Secondary Endpoints of Phase II/III Study Confirm Clear Benefits from Treatment With removab(R) for Patients with Malignant Ascites
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Apr 2007
GANYMED Raises Euro 33.7 Million in Series C Financing Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Dec 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 15

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 15 additional stories matching:
eFFECTOR
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!